March 31st 2023
Though there is no current FDA-approved treatment, lotilaner ophthalmic solution, 0.25%, is the first drug designed to treat and target the underlying cause of Demodex blepharitis.
Community Practice Connections™: Novel Therapies for Neovascular Retinal Disease – Expert Analysis of New Key Data
View More
Practical Approaches to Modern Dry Eye Treatment and Management
June 25, 2025
Register Now!
Latest Advances in X-Linked Retinitis Pigmentosa: Optimizing Diagnosis and Developments in Gene Therapy
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (CME Track)
View More
Community Practice Connections™: Innovations and Interdisciplinary Approaches in Glaucoma Management—Expanding the Treatment Arsenal (COPE Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (CME Track)
View More
Road Mapping the Treat-and-Extend Protocol in nAMD and DME – When Time Is Sight (COPE Track)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (CME Credit)
View More
Community Practice Connections™: Navigating Complexities in Neurotrophic Keratitis — A Roadmap for Advanced Patient Care (COPE Credit)
View More
Retina Specialists: Join us in Long Beach
July 31, 2025 - August 2, 2025
Register Now!
SimulatED™: Pioneering Treat-and-Extend Therapy—The Impact of Early Application
View More
3rd Annual IKA Keratoconus Symposium: Front to Back and Everything in Between
September 6, 2025
Register Now!
Clinical Consultations™: Novel Therapeutic Targets in Neovascular Retinal Diseases – A Focus on the Roles of VEGF-C/D
View More
EyeCon 2025
September 26-27, 2025
Register Now!
Optometrists: Earn COPE CE Credits in Portland or Virtually
October 16-17, 2025
Register Now!
Join us at The Ophthalmology Meeting in Orlando this October
October 18, 2025
Register Now!
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (Cope Credit)
View More
Rapid Reviews in Retina™: Emerging Updates from Winter 2024 – Addressing the Wealth of New Data in Treatments for nAMD and DME (CME Track)
View More
(CME) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
(COPE) Optimizing Management of Ocular Toxicity in Cancer Patients: The Role of Ophthalmologists in the Spectrum of Care
View More
Expert Perspectives on Technological Advances in Cataract Surgery
View More
Expanding Treatment Options for Demodex Blepharitis: Patient-Centric Approaches to Therapy
View More
Burst CME™ Part 3: Initiating Early Intervention in Patients With Glaucoma Who Fail Pharmacological Therapy
View More
(CME Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
Interventional Glaucoma Treatment: Evolving Paradigms for Addressing Unmet Needs
View More
(CME Track) Burst CME™ Part 1: Insights Into Glaucoma and the Need for Early Intervention
View More
(COPE Credit) Community Practice Connections™: Applying Advances in Neovascular Retinal Disease - Expanding Treatment Intervals & Enhancing Outcomes
View More
(CME Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(COPE Track) Neurotrophic Keratitis in Focus – From Early Recognition to Strategic Intervention
View More
(CME Track) Leveraging Rho Kinase Inhibition in Glaucoma Management — How Can Novel Treatment Pathways Impact Patient Outcomes?
View More
How to treat patients with delusional parasitosis
November 14th 2017Delusional parasitosis or Ekbom’s syndrome is a patient’s mistaken belief that he is infested by parasites such as mites, lice, fleas, spiders, worms, bacteria, or other organisms. Scott Schachter, OD, discusses the challenges ODs face when working with these patients.
Treating blepharitis in the pediatric population
June 1st 2017When your pediatric patient presents with irritated, itchy eyelids with reddened lid margins, diagnosing blepharitis may be the easy part of patient care. Implementing a treatment regimen for patients who are infants, toddlers, or school-age children, requires optometrists to use not only their knowledge but their clinical art of practice as well.
Understanding and defining MGD
August 3rd 2016The Tear Film and Ocular Surface Society’s Meibomian Gland Workshop was tasked to sort through the literature to determine proper terminology of conditions affecting the lid margin. Review the terminology, gland anatomy, gland expression classifications, and treatment strategies.
5 ways to go beyond baby shampoo for lid hygiene
June 24th 2016Certainly, one would assume that nothing could be safer than a product designed for use with children. Television commercials with smiling, happy babies covered in frothy bubbles imply the product is harmless. Ubiquitous marketing alone creates a subconscious sense of safety for both doctor and patient.
How MGD can work for your practice
May 3rd 2016Dry eye represents a major opportunity with more than 25 million people suffering from the condition in the U.S.,1 and meibomian gland dysfunction (MGD) is thought to be the most common cause of dry eye.2 During a session at SECO, Walt Whitley, OD, MBA, FAAO, shared his tips for making the most of this opportunity in your practice.
What’s all the craze about demodex?
March 23rd 2016While many eyecare practitioners (ECPs) are just now learning about Demodex infestation of the eyelids and adnexa, the fact is that this condition has been around for as long as mankind. The entomologists Johannsen and Riley from Cornell University first described the species in detail anatomically as early as 1915, but it wasn’t until the 1960s that clinical reports of demodex-related blepharitis began to emerge in the literature.
Why you’re missing the dry eye right in front of you
December 9th 2015A common barrier to many practitioners is the concern that their practice does not have the patient foundation to make investment in the services economically profitable. I assure you that OSD management will profit the patient in many ways that includes clearer, more comfortable vision, enhancing their productivity and overall wellbeing.
The connection between dry eye and eyelashes
September 30th 2015While there are a myriad of associated concerns due to ocular surface inflammation, a few eyelash-related complications of note are trichiasis, acquired distachiasis, local madarosis, and poliosis. Each of these is in some way connected to dry eye.